Peripheral artery disease affects more than 200 million people worldwide and is driven by the progressive narrowing of arteries outside the heart, most often in the femoropopliteal segment of the leg, where atherosclerosis, thrombosis, and calcification combine to choke off blood supply. In its most severe form, critical limb ischemia, patients suffer rest pain, non-healing wounds, and a high risk of amputation. The standard treatment is endovascular revascularization—typically balloon angioplasty and stenting—but severe calcification stiffens the vessel wall, causing elastic recoil, dissection, and difficulty delivering and expanding devices. Orbital atherectomy was engineered to solve this problem. It uses a diamond-coated crown that orbits eccentrically inside the artery, sanding down calcified plaque while theoretically sparing the vessel from deep injury. The device has been reported to generate microparticles averaging roughly two micrometers in diameter—smaller than red blood cells—suggesting that the debris it produces would be too fine to cause clinically significant blockages downstream.

That assumption has now been directly tested. Researchers at the University of Nebraska Omaha and the University of Nebraska Medical Center obtained ten human femoropopliteal artery segments from tissue donors, all with advanced atherosclerosis and calcification. Nine of the donors were male, with a mean age of 77 years, and the donor cohort reflected the typical risk profile of the disease: all had hypertension, half had diabetes and chronic kidney disease, most had dyslipidemia, and nearly all had smoked. Each artery was mounted in a custom pulsatile flow loop designed to approximate the hemodynamics of the leg artery under resting conditions, complete with a compliance chamber, real-time pressure and flow sensors, and a 100-micrometer filter positioned downstream to capture anything the treatment dislodged.

The experimental protocol mirrored clinical practice. Each vessel underwent baseline imaging and hemodynamic assessment, then treatment with the Diamondback 360 orbital atherectomy system over its dedicated guidewire, with passes at rotational speeds of 60, 90, and 140 thousand revolutions per minute, followed by balloon angioplasty with semi-compliant balloons inflated to nominal pressure. At each stage, micro-computed tomography at voxel resolutions of 50 to 55 micrometers quantified the flow lumen, pressure transducers measured the translesional mean arterial pressure gradient, an ultrasonic flow meter recorded net flow, and the downstream filter was photographed and analyzed with custom image-analysis software to quantify every captured particle.

The headline finding concerns the debris. Orbital atherectomy generated embolic material with a mean captured area of 0.386 square millimeters per particle distribution, and the sizes were alarming: 90 percent of the arteries released fragments of at least 1 millimeter, and 10 percent shed fragments exceeding 5 millimeters—debris capable of obstructing the popliteal or femoral arteries themselves. On average, each specimen released about 87 particles small enough to occlude arterioles, 19 particles in the range of perforator arteries, and roughly 5.5 particles that could block digital arteries, with half to 60 percent of specimens producing emboli in the size range of plantar and tibial vessels. Subsequent balloon angioplasty added smaller debris, averaging 0.143 square millimeters, apparently dislodging plaque that the atherectomy had already loosened. Because embolic protection filters in clinical use may not capture fragments this large, the authors argue the implications for patient safety are considerable.

The study also quantified the benefits that have made the device popular. Flow lumen volume increased significantly and additively across treatment stages, rising by a total of 0.409 milliliters from baseline to after both interventions, with orbital atherectomy contributing 0.180 milliliters and balloon angioplasty adding another 0.229 milliliters. Inner-diameter pulsatility—a measure of how much the lumen itself expands with each heartbeat, and a proxy for luminal compliance—increased from 1.5 percent at baseline to 2.3 percent after the combined treatment, a statistically significant improvement. These results support the core concept behind plaque modification: sanding away calcium does make the channel larger and more distensible, potentially reducing the need for high-pressure ballooning and bailout stenting, a benefit previously reported in trials such as COMPLIANCE 360, which found bailout stenting in just 5.3 percent of atherectomy patients versus 77.8 percent with balloon angioplasty alone.

But the hemodynamic gains were strikingly uneven. The translesional pressure gradient fell by a clinically meaningful margin of more than 10 millimeters of mercury in only 40 percent of the arteries, showed minimal improvement in 50 percent, and actually worsened in 10 percent, in one case because a flow-limiting dissection was created. Net flow improved by at least a quarter in 40 percent of specimens but was unchanged in 30 percent and decreased in the remaining 30 percent, including one artery that lost 41 percent of its flow due to dissection. Dissections were a frequent companion of the treatment, typically occurring at the interface between plaque and vessel wall, and were often exacerbated by the subsequent ballooning. Notably, while the inner lumen became more distensible, the outer diameter pulsatility—measured with both duplex ultrasound and a high-resolution external camera—did not change, suggesting the procedure improves luminal compliance without fundamentally altering the stiffness of the vessel wall itself.

These bench findings dovetail with a growing body of clinical evidence. In the Vascular Study Group of New England registry, orbital atherectomy carried a 4.3 percent embolization rate—77 percent higher than balloon angioplasty and 64 percent higher than stenting—and 68 percent of those embolic events required additional intervention, including open surgery in 11 percent of cases. The LIBERTY 360 registry reported embolization in 7.8 percent of diabetic patients with critical limb ischemia treated with the device, four times the rate seen in non-diabetics. A recent Japanese study of rotational atherectomy with active aspiration found angiographic embolization in more than a third of calcified femoropopliteal procedures and true embolic events in over half. Meanwhile, large analyses of Vascular Quality Initiative and Medicare data have linked atherectomy overall to a 3.7-fold higher risk of major amputation compared with stenting and a 1.5-fold higher risk compared with balloon angioplasty, alongside more major adverse limb events.

The economics add another layer of concern. The Diamondback 360 catheter costs 3,795 dollars in the United States, the average index procedure costs 11,729 dollars, and two-year peripheral artery disease-related costs with atherectomy exceed those of balloon angioplasty or stenting by 6,500 to 8,000 dollars. Medicare outpatient spending on atherectomy ballooned from 86 million dollars in 2011 to 612 million dollars in 2021, a trajectory that has drawn national scrutiny. Against that backdrop, the new study’s authors argue that orbital atherectomy is best reserved for patients with severely calcified lesions in whom plaque modification offers a clear procedural advantage, and should be used cautiously, if at all, in patients at elevated risk of clinically significant distal embolization or when comparable revascularization can be achieved less aggressively. Embolic protection devices, they note, deserve renewed attention given the fragment sizes observed.

The authors are careful to acknowledge the limits of their model. The sample of ten arteries limited statistical power; the specimens were cadaveric and lacked vasoreactivity, healing responses, and thrombosis; the absence of surrounding soft tissue may have altered how the crown interacted with the wall, potentially underestimating debris generation; and the standardized treatment protocol could not capture the operator-dependent variability of real-world practice. Still, the study is the first to systematically combine micro-CT imaging, physiological flow simulation, embolic capture, and pulsatility measurement on the same human arteries across sequential treatment stages, and its central conclusion is difficult to escape: the plaque-modifying benefits of orbital atherectomy are real, but they come bundled with a consistent and substantial shower of embolic debris and vessel wall injury that may explain why the device’s procedural successes have not translated into the superior long-term patency and limb salvage that patients and clinicians hoped for.

Subject of Research: Biomechanical and embolic effects of orbital atherectomy in calcified human femoropopliteal arteries

Article Title: High Embolic Risk with Orbital Atherectomy for Calcified Peripheral Artery Disease

Article References: Gilyazov, R., de Oliveira, B. B., Glushkov, M., Deegan, P., MacTaggart, J., & Kamenskiy, A. (2026). High Embolic Risk with Orbital Atherectomy for Calcified Peripheral Artery Disease. Annals of Biomedical Engineering. https://doi.org/10.1007/s10439-026-04370-9

Image Credits: AI Generated

DOI: 10.1007/s10439-026-04370-9

Keywords: peripheral artery disease, orbital atherectomy, embolization, vascular calcification, femoropopliteal artery, balloon angioplasty, critical limb ischemia, endovascular revascularization, arterial compliance, embolic debris, vessel dissection, biomechanics

Vascular calcification, the pathological deposition of calcium phosphate minerals within the walls of blood vessels, is one of the most consequential yet least tractable complications of aging, chronic kidney disease, diabetes, and atherosclerosis. Once calcium crystals begin to accumulate in the arterial media or intima, vessels stiffen, lose their elastic recoil, and become far more likely to trigger heart attacks, strokes, and sudden cardiac death. Clinicians can detect calcification readily with imaging, but they have few tools to reverse it. The new work suggests that the body may already possess a natural braking system against this process, one encoded in a stretch of DNA that no one thought produced a protein at all.

The central character in the story is pyruvate kinase M2, or PKM2, an enzyme that sits at a critical junction of glucose metabolism, catalyzing the final step of glycolysis. PKM2 has long been known to moonlight beyond its enzymatic role, participating in gene regulation and cell proliferation, and it has been repeatedly implicated in vascular disease. When vascular smooth muscle cells, the contractile workhorses of the artery wall, are stressed by high phosphate, inflammatory signals, or uremic toxins, they undergo a striking identity change: they downregulate their muscle-like program and begin acting like bone-forming osteoblasts, laying down mineral instead of maintaining vessel elasticity. PKM2 has emerged as a facilitator of this osteogenic switch, making it an attractive target for intervention.

The researchers behind the new study identified PKM2 AP as a micropeptide, a translation product of a short open reading frame that yields a peptide far too small to fold into a conventional enzyme or receptor. For decades, such sequences were considered too short to matter, and they were routinely excluded from genome annotations. That assumption has been steadily dismantled as ribosome profiling and mass spectrometry have revealed hundreds of small peptides actively produced in human cells, many of which carry out discrete regulatory tasks. PKM2 AP now joins this class with a particularly elegant mechanism of action.

According to the study, PKM2 AP functions as what structural and chemical biologists call a molecular glue. Molecular glues are small molecules or peptide-like factors that bind simultaneously to a target protein and to a component of the ubiquitin ligase system, inducing an otherwise nonexistent or fortuitous interaction. The result is that the target protein, in this case PKM2, becomes flagged with ubiquitin chains, the universal degradation tags of the cell, and is delivered to the proteasome for destruction. Rather than blocking PKM2’s activity with an inhibitor, the micropeptide simply causes the enzyme to disappear, an approach that mirrors the strategy behind a new generation of targeted protein degraders now transforming drug development.

The consequences of this degradation cascade through the calcification program. With PKM2 levels reduced, the metabolic and transcriptional signals that push vascular smooth muscle cells toward an osteoblast-like fate lose their momentum. In experimental models, the presence of PKM2 AP correlated with diminished osteogenic marker expression, reduced mineralization of the extracellular matrix, and preserved contractile phenotype of the vessel wall cells. The authors present the micropeptide as a previously unrecognized endogenous inhibitor of vascular calcification, one that operates not at the level of mineral chemistry but at the level of cell fate determination.

What makes the mechanism especially notable is its selectivity. Broadly suppressing PKM2 throughout the body would be undesirable, given the enzyme’s central role in glycolysis in virtually every tissue. A molecular glue strategy that depends on a specific ternary complex, the micropeptide bridging PKM2 and the ubiquitination machinery, offers a degree of precision that small-molecule inhibitors often lack. The interaction surfaces involved are typically more extensive than those of a conventional drug, which can translate into tighter discrimination between the intended target and lookalike proteins. This selectivity principle is precisely what has made molecular glues, from the thalidomide derivatives used in multiple myeloma to engineered degraders in the laboratory, one of the most actively pursued frontiers in pharmacology.

The study also carries implications for how scientists think about the noncoding genome. PKM2 AP arises from a locus that would appear in standard annotations as a noncoding RNA or an untranslated region. Its discovery underscores that the boundary between coding and noncoding is blurrier than textbooks suggest, and that some of the most medically relevant gene products may be hiding in regions cataloged as silent. Similar stories have unfolded in recent years with micropeptides implicated in muscle regeneration, cardiac stress responses, and cancer metabolism, and each new example strengthens the case for systematically annotating small open reading frames across the human genome.

From a translational standpoint, the path forward is demanding but clear. The researchers will need to demonstrate that PKM2 AP, or a stabilized mimic of it, can slow or reverse calcification in animal models of chronic kidney disease and atherosclerosis, and ultimately in patients whose arteries are already stiffening. Micropeptides face familiar delivery challenges: they are small enough to be degraded quickly and may not cross cell membranes without assistance. Yet the molecular glue concept offers a workaround, since a conventional small molecule that reproduces the same PKM2-ligase bridging interaction could, in principle, be developed through screening and structure-based design. If such a compound emerged, it would represent a fundamentally new class of anti-calcification therapy, one that reprograms vascular cell identity rather than chelating calcium after the fact.

For now, the discovery stands as a vivid illustration of biology’s economy: a peptide of a few dozen amino acids, encoded by a genomic footnote, holds the power to decide whether an artery stays supple or turns to stone. As the population ages and calcific vascular disease continues to drive cardiovascular mortality worldwide, the humble micropeptide may prove to be one of the more consequential molecules to emerge from the dark matter of the genome.

Subject of Research: A micropeptide that inhibits vascular calcification through molecular glue-mediated ubiquitination of PKM2

Article Title: PKM2 AP: a micropeptide inhibits vascular calcification via molecular glue-mediated ubiquitination of PKM2

Article References: Wang, M., Cheng, J., Ma, L., Yang, J., Gao, C., Fang, X., Ma, L., Fu, X., Lin, A., Ying, S., Lin, W., & Yang, Y. (2026). PKM2 AP: a micropeptide inhibits vascular calcification via molecular glue-mediated ubiquitination of PKM2. Nature Communications. https://doi.org/10.1038/s41467-026-77693-9

Image Credits: AI Generated

DOI: 10.1038/s41467-026-77693-9

Keywords: vascular calcification, micropeptide, PKM2, molecular glue, ubiquitination, protein degradation, vascular smooth muscle cells, glycolysis, noncoding genome, cardiovascular disease, proteasome, osteogenic switch

The research team, led by Bing-Hao Lu, Wei-Han Lin, and Kuo-Yuan Huang, focused on a group of patients who are, in many respects, the clinical frontline of the osteoporosis epidemic: 230 hospitalized adults who had undergone surgery for fragility fractures of the hip or spine. These are the fractures that occur when a fall from standing height, or even a trivial mechanical insult, is enough to break bone weakened by age-related mineral loss. Hip fractures in particular carry a grim prognosis, with prior meta-analyses showing excess mortality that persists for years after the injury, alongside substantial long-term disability. Identifying better tools to stratify skeletal risk in such patients is therefore not an academic exercise but a pressing clinical need, because the first fragility fracture is one of the strongest predictors that a second one will follow.

Abdominal aortic calcification offers an attractive candidate marker because it can be observed on imaging that many of these patients already undergo. The researchers quantified AAC on lateral spine radiographs using the 24-point Kauppila score, a well-established semiquantitative index that grades the severity of calcified deposits along both the anterior and posterior walls of the aorta across four lumbar vertebral segments. By summing the scores at each level, the method yields a continuous measure of calcification burden ranging from zero to 24. The technique has a long pedigree: it was first developed in the Framingham Heart Study population, where aortic calcific deposits were shown to predict vascular morbidity and mortality, and it has since been adapted for use with dual-energy X-ray absorptiometry images, potentially allowing osteoporosis screening visits to double as vascular assessments.

The biological rationale for a bone-vascular link is compelling. Both bone mineralization and vascular calcification involve the deposition of calcium phosphate crystals, but they sit at opposite ends of a regulatory spectrum. Cells in the vascular wall, under conditions of oxidative stress, inflammation, disordered mineral metabolism, and aging, can adopt an osteoblast-like phenotype and actively lay down bone-like matrix within the artery. Meanwhile, the same molecular pathways, including osteoprotegerin, bone morphogenetic proteins, and vitamin K–dependent proteins such as matrix Gla protein, participate in regulating both processes. Epidemiological evidence has repeatedly connected the two: lower bone mineral density has been associated with coronary artery calcium, and aortic calcification has been linked to bone loss over 25-year follow-up in the Framingham cohort. Systematic reviews and meta-analyses of observational studies have reported that higher AAC burden is associated with lower bone mineral density and increased fracture risk in general populations.

Against this backdrop, the Taiwanese team set out to test whether AAC could meaningfully stratify skeletal outcomes in patients who had already fractured. They examined associations between AAC burden and bone mineral density measured by dual-energy X-ray absorptiometry, with particular attention to the femoral neck, the site most relevant to hip fracture. They also explored relationships with FRAX-estimated fracture probabilities, the widely used algorithm that integrates clinical risk factors with or without bone density to estimate ten-year fracture likelihood. Fracture severity was graded using established classification systems, including the semiquantitative method for vertebral fractures and the Garden and Evans classifications for femoral neck and trochanteric hip fractures, respectively. Finally, the investigators tracked refracture over time using Kaplan-Meier survival curves and Cox proportional hazards models, anchoring all follow-up to a common baseline defined as the latest of three dates: the index operation, the bone density scan, and the radiographic AAC assessment.

The headline result was a genuine but fragile association. In unadjusted analyses, higher AAC scores were significantly correlated with lower femoral neck bone mineral density, with a Spearman correlation coefficient of −0.230 and a p-value below 0.001. This is consistent with the broader literature and suggests that, at the crude level, calcified arteries and demineralized femoral necks do travel together in fracture patients, just as they do in community cohorts. However, when the researchers adjusted for potential confounders in multivariable regression models, the association was attenuated and lost its independent statistical footing. In other words, much of the apparent relationship between aortic calcification and low bone density in these patients could be explained by factors that AAC and bone density share in common: advancing age, sex, and body-composition characteristics.

The same pattern of attenuated significance held for the other skeletal outcomes. Although AAC showed weak positive correlations with FRAX-estimated probabilities of major osteoporotic and hip fracture, it did not independently predict the severity of the vertebral or hip fractures that brought these patients to the operating room in the first place. A more severe calcification burden did not translate into a more comminuted fracture, a higher-grade compression deformity, or a worse anatomic pattern. This finding cuts against the intuitive expectation that vascular disease and skeletal fragility would progress in lockstep, even within a population already selected for having sustained a fragility fracture.

Perhaps the most clinically consequential result concerned refracture risk. Among the 224 patients who could be followed from the common baseline, 24 experienced a first refracture during the observation period. Refracture-free survival, plotted by Kaplan-Meier analysis, did not differ between patients with higher and lower AAC burdens, and the log-rank test yielded a p-value of 0.982, indicating near-identical curves. In the multivariable Cox model, high AAC was not associated with refracture risk, with a hazard ratio of 0.90 and a 95 percent confidence interval of 0.38 to 2.15, spanning unity comfortably. The authors are appropriately cautious here, noting that the refracture analysis should be interpreted as exploratory because the number of events was limited, which widens confidence intervals and reduces the study’s power to detect modest effects. Still, the direction of the result offers no encouragement that AAC adds predictive value in this setting.

The broader significance of the study lies in what it says about context dependence in biomarker research. Most of the evidence linking AAC to skeletal outcomes comes from community-dwelling populations undergoing routine osteoporosis screening, where recent work, including automated AAC quantification combined with trabecular bone score, has suggested independent fracture prediction. But patients who have already fractured and require hospitalization and surgical fixation represent a different clinical universe: they are older, frailer, and closer to the severe end of the bone-vascular disease spectrum. Within such a selected cohort, the variance in skeletal health attributable to vascular calcification may already be absorbed by the very fact of the fracture, and by the demographic and body-composition factors that drove both processes. The authors conclude that AAC showed limited independent value for skeletal stratification in this inpatient cohort beyond shared demographic and body-composition factors. For clinicians, the message is that a calcified aorta glimpsed on a lateral spine film should not be treated as a surrogate for a fragile skeleton or a forthcoming refracture in fracture patients, even as it retains well-documented value as a marker of cardiovascular risk. For researchers, the study is a reminder that biomarkers validated in screening populations must earn their place, study by study, in the more complex terrain of acute fracture care.

One practical implication concerns how AAC is measured in routine care. Because the Kauppila scoring system can be applied to lateral spine images acquired during standard densitometry, vascular calcification assessment requires no additional radiation exposure or cost, which explains much of the enthusiasm for integrating it into fracture risk workflows. The present findings temper that enthusiasm for inpatient populations, but they do not negate the score’s established role in cardiovascular prognostication, where meta-analytic evidence links aortic calcification to incident vascular events and mortality.

Several design features of the study merit consideration when weighing its conclusions. The retrospective single-center design means that AAC burden was quantified from radiographs obtained for clinical rather than research purposes, and the timing of imaging relative to the index fracture may have varied across patients. The modest sample size of 230, while respectable for an inpatient fracture cohort, limits the precision of adjusted estimates, and the 24 refracture events provide only coarse resolution for survival modeling. Selection factors inherent to hospitalization, including the decision to obtain lateral spine imaging and DXA, may also have shaped the cohort in ways that are difficult to quantify. Future prospective studies with standardized imaging protocols, larger event counts, and longer follow-up will be needed to determine whether AAC retains any incremental prognostic value once fracture has occurred, or whether its utility remains confined to community screening settings.

Subject of Research: The association between abdominal aortic calcification and bone mineral density, fracture severity, and refracture risk in hospitalized patients with surgically treated fragility fractures.

Article Title: Abdominal aortic calcification and skeletal outcomes in hospitalized patients with surgically treated fragility fractures: a retrospective cohort study

Article References: Lu, B.-H., Lin, W.-H., & Huang, K.-Y. (2026). Abdominal aortic calcification and skeletal outcomes in hospitalized patients with surgically treated fragility fractures: a retrospective cohort study. Archives of Osteoporosis, 21(1), Article 137. https://doi.org/10.1007/s11657-026-01755-0

Image Credits: AI Generated

DOI: 10.1007/s11657-026-01755-0

Keywords: abdominal aortic calcification, bone mineral density, fragility fracture, refracture, osteoporosis, FRAX, Kauppila score, hip fracture, vertebral fracture, vascular calcification, dual-energy X-ray absorptiometry, retrospective cohort study